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ffect of Perindopril on the Onset and Progression of
eft Ventricular Dysfunction in Duchenne Muscular Dystrophy
enis Duboc, MD, PHD,* Christophe Meune, MD,* Guy Lerebours, MD,† Jean-Yves Devaux, MD, PHD,*
uy Vaksmann, MD,* Henri-Marc Bécane, MD*
aris, France
OBJECTIVES The aim of this research was to examine the effects of perindopril on cardiac function in
patients with Duchenne muscular dystrophy (DMD).
BACKGROUND Duchenne muscular dystrophy, an inherited X-linked disease, is characterized by progressive
muscle weakness and myocardial involvement.
METHODS In phase I, 57 children with DMD and a left ventricular ejection fraction (LVEF) 55% (mean
65.0  5.4%), 9.5 to 13 years of age (mean 10.7  1.2 years), were enrolled in a three-year
multicenter, randomized, double-blind trial of perindopril, 2 to 4 mg/day (group 1), versus placebo
(group 2). In phase II, all patients received open-label perindopril for 24 more months; LVEF was
measured at 0, 36, and 60 months.
RESULTS Phase I was completed by 56 (27 in group 1 and 29 in group 2) and phase II by 51 patients
(24 in group 1 and 27 in group 2). There was no difference in baseline characteristics between
the treatment groups. At the end of phase I, mean LVEF was 60.7  7.6% in group 1 versus
64.4  9.8% in group 2, and was 45% in a single patient in each group (p  NS). At 60
months, LVEF was 58.6  8.1% in group 1 versus 56.0  15.5% in group 2 (p  NS). A
single patient had an LVEF 45% in group 1 versus eight patients in group 2 (p  0.02).
CONCLUSIONS Early treatment with perindopril delayed the onset and progression of prominent left ventricle
dysfunction in children with DMD. (J Am Coll Cardiol 2005;45:855–7) © 2005 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.09.078American College of Cardiology Foundation
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iuchenne muscular dystrophy (DMD), an inherited
-linked disease associated with absence of dystrophin (1),
s characterized by progressive muscle weakness and ines-
apable cardiac involvement (1,2), fatal in approximately
0% of patients (3,4). Angiotensin-converting enzyme in-
ibitors (ACEI) are effective in overt congestive heart
ailure (CHF) (5) and have prophylactic effects in the Syrian
amster, an experimental model of beta-sarcoglycanopathy
henotypically similar to DMD (6,7).
See page 858
This study examined the preventive effects of the ACEI,
erindopril, on the onset and progression of left ventricular
LV) dysfunction in children with DMD and a normal left
entricular ejection fraction (LVEF).
ETHODS
his study was approved by the appropriate ethical review
ommittees, and informed written consent was granted by
he parents or legal guardians of all patients. Children
etween the ages of 9.5 and 13 years with genetically proven
MD, normal cardiac examination, and a radionuclide
From the *French Working Group of Heart Involvement in Myopathies Investigators,
aris, France; and †Servier Laboratories, Paris, France. This study was supported by
rants from the French Association Against Myopathies and from Servier Laboratories.a
Manuscript received March 2, 2004; revised manuscript received August 5, 2004,
ccepted September 13, 2004.VEF 55% were included in the study provided they: 1)
olerated a 1-mg test dose of perindopril; and 2) had a
ystolic blood pressure 80 mm Hg in the supine or 70
m Hg in the sitting position. Patients treated with
ardioactive drugs, or with a blood urea nitrogen 7
mol/l, or contraindications to ACEI therapy were not
ncluded.
tudy protocol. This two-phase study was conducted at 10
edical institutions (Appendix). In a double-blind phase I,
atients were randomly assigned to perindopril 2 to 4 mg daily
s tolerated (group 1), or equivalent placebo (group 2), for three
ears. In phase II, both groups were treated with open-label
erindopril, 2 to 4 mg daily, for two additional years. Other
ardioactive medications were allowed in phase II, if indicated.
utcome measures. All patients underwent detailed, se-
ial, clinical, and drug tolerance evaluations, and routine
aboratory screens. Resting radionuclide ventriculography
as performed at baseline, 36 months, and 60 months, after
n vitro erythrocyte labeling with 500 to 740 MBq
echnetium-99m, and analyzed in the nuclear medicine
epartment of Cochin Hospital’s core laboratory by two
xperts blinded to other study data.
The primary study end points were a reduction in mean
VEF, and in the number of patients whose LVEF fell
elow 45%. The cut-off value of 45% was predefined on the
asis of prior studies where an LVEF 40% was an
mportant prognostic factor in adults (8), and on the basis of
normal LVEF 5% higher in children than in adults in our
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Perindopril in Duchenne Disease March 15, 2005:855–7aboratory. Clinical data and tolerance of study drug were
econdary end points.
tatistical analyses. Data, expressed as means  SD, were
nalyzed according to the intention-to-treat principle, and
VEF measurements available were included in the analysis
t each time point. Student t tests were used for normally
istributed continuous variables, and chi-square analysis for
ifferences in frequencies (p value 0.05 for significance).
ESULTS
mong 80 consecutive children screened, DMD was not
onfirmed genetically in 3, and 20 had an LVEF 55%
mean 45.6  7.0%). Thus, 57 patients were included (28
andomly allocated to group 1, 29 randomly allocated to
roup 2). There was no difference in baseline characteristics
etween the two treatment groups (Table 1).
hase I. Among 56 patients who completed phase I, at
east one adverse event was reported by 19 patients in
roup 1, versus 17 patients in group 2 (Table 2).
V FUNCTION. At 36 months, LVEF remained normal in
he majority of patients, and mean LVEF was similar in
oth groups. One patient did not complete phase I, though
ad remained free of cardiovascular event or symptoms at 36
onths; LVEF was45% in a single patient in each group.
hase II. In phase II, three patients from group 1 and two
rom group 2 withdrew from the study for personal reasons.
one of these five patients experienced an adverse clinical
vent during that period. Beta-adrenergic blockers were
rescribed for treatment of supraventricular arrhythmias in
our patients in group 1 and five in group 2. No patient
eceived diuretics or other cardioactive drugs. Mean LVEF
ecreased from 65.0  5.5% at baseline to 58.6  8.1% at
0 months in group 1 (p  0.001), and from 65.4  5.5%
o 56.0  15.5% in group 2 (p  0.006). The difference in
ean LVEF between the two groups was not statistically
ignificant. A single patient in group 1 had an LVEF45%
ersus eight in group 2, including the patient with an LVEF
45% at the end of phase I (chi-square 5.669, p  0.02)
Fig. 1). The mean age of patients with versus without
epressed LVEF was similar, and no difference was ob-
erved when comparing the effects of 2 versus 4 mg of
erindopril. No patient treated with a beta-adrenergic
locker during phase II had an LVEF 45% at the end of
he study. Finally, three patients, who all had an LVEF
45%, died of CHF during an additional year of follow-up
Abbreviations and Acronyms
ACEI  angiotensin-converting enzyme inhibitors
CHF  congestive heart failure
DMD  Duchenne muscular dystrophy
LV  left ventricle/ventricular
LVEF  left ventricular ejection fractionn group 2, versus none in group 1 (p  0.08). VISCUSSION
he main findings of our study were: 1) perindopril admin-
stered for 60 months had a preventive effect in children
ith DMD and normal LVEF between the ages of 9.5 and
3 years; 2) in a dose of 2 to 4 mg/day, perindopril was well
olerated; and 3) LVEF was depressed in 25% of DMD
atients before the age of 13 years.
The management of cardiac involvement in DMD is
enerally supportive and includes ACEI (5). In this study,
owever, we documented a prophylactic effect of perindo-
ril. This may have important clinical implications, because
V systolic function, unlike ventricular arrhythmias or the
tandard or signal-averaged electrocardiogram, is a con-
rmed, powerful prognostic factor in DMD (9). Although
ur study had been planned for five years, the finding of a
rend toward a lower mortality in group 1 at six years of
ollow-up reinforces our results. Combined with the toler-
nce of therapy, this suggests that DMD patients should be
reated with perindopril as early as 9.5 years of age,
egardless of LVEF.
The benefit conferred by perindopril was manifest in the
revention of a decrease in LVEF below 45% at 60 months.
o significant difference between the treatment groups was
resent at the end of the double-blind period, and no
ifference in mean LVEF was observed at 60 months. The
bsence of a more prominent treatment effect may have
able 1. Baseline Characteristics of Study Groups
Group 1
(n  28)
Group 2
(n  29)
ge, yrs 10.7  1.2 10.6  1.2
eight, kg 37.1  10.1 37.5  13.8
eight, cm 141  10 139  14
ystolic blood pressure, mm Hg 109  12 105  8
iastolic blood pressure, mm Hg 64  9 61  12
eart rate, beats/min 94  12 99  15
VEF, % 65.0  5.5 65.4  5.5
reatment daily dose of study drug, n
2 mg 9 12
4 mg 19 17
nless specified otherwise, values are means  SD. Between-group differences are
tatistically nonsignificant.
LVEF  left ventricular ejection fraction.
able 2. Adverse Events During the Study
Group 1
(n  28)
Group 2
(n  29)
ronchitis 2 5
ough 2 3
hinitis 2 3
eight loss 3 2
ever 2 2
eadache 2 2
iarrhea 0 2
inor allergic reactions 0 2
yperkalemia 0 0
enal insufficiency 0 0alues indicate numbers of patients.
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aseline LV function, who were, a priori, at lower risk of
arly cardiac involvement, as confirmed by a preserved
VEF up to 60 months in most patients. The small
opulation studied may also explain the 60-month delay in
he development of significant differences between the two
tudy groups. On the other hand, one may wonder why
erindopril was apparently ineffective in preventing a de-
rease in LVEF in group 2 during phase II. In the absence
f a control group during phase II, however, one cannot
onclude that ACEI perindopril was ineffective. Further-
ore, because: 1) cardiac involvement is inescapable in DMD;
nd 2) our population was older when entering phase II,
ardiac involvement may have been present at study entry in
ome children assigned to placebo, although undetectable by
adionuclide ventriculography, and the delayed initiation of
CEI treatment may have failed to prevent further progression
f LV dysfunction during phase II (3). This highlights the
mportance of more sensitive methods of assessment, such
s tissue-Doppler echocardiography (10), when planning
imilar studies.
igure 1. Distribution of left ventricular ejection fraction (LVEF) in
roups 1 and 2 at study entry, 36 months, and 60 months of follow-up.
Corresponds to the difference in the number of patients with LVEF
45% in each group. Red circles  group 1 (initially assigned to
erindopril); black circles  group 2 (initially assigned to placebo).Our observations also illustrate the variable evolution of iarly cardiac involvement in DMD, and the high prevalence
f depressed LVEF before 13 years of age. This suggests
hat studies of preventive treatment with perindopril at a
ounger age are warranted.
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PPENDIX
or a list of the French investigators and institutions that
articipated in the study, please see the March 15, 2005,
ssue of JACC at www.onlinejacc.org.
